The objective of ESPAC-TPlus is to identify markers in the primary tumour which predict improved probability of survival for either adjuvant 5-FU or gemcitabine following resection for pancreatic ductal adenocarcinoma.
Primary Outcome
Secondary outcomes
Admin/Site Area
Sorry there are currently no job vacancies
"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)
Read more Patient stories